Publications in collaboration with researchers from Universidad Complutense de Madrid (36)

2024

  1. Incidence and clinical impact of inappropriate periprocedural and perioperative management of antiplatelet therapy

    Medicina Clinica, Vol. 163, Núm. 7, pp. 336-343

  2. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 7, Núm. 3, pp. e240809

  3. Periprocedural use of antithrombotic therapy in interventional cardiology in Spain: are we doing better than other specialties?

    Revista Espanola de Cardiologia, Vol. 77, Núm. 8, pp. 701-703

2023

  1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  2. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 8-15

  3. Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial

    JAMA Internal Medicine, Vol. 183, Núm. 5, pp. 407-415

  4. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

  5. Post-COVID-19 syndrome and diabetes mellitus: a propensity-matched analysis of the International HOPE-II COVID-19 Registry

    Frontiers in Endocrinology, Vol. 14

  6. Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in “real world”: the REQXAA study

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 729-738

2022

  1. Current trends on antithrombotic therapy

    REC: CardioClinics

  2. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  3. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights

    Trials, Vol. 23, Núm. 1

2021

  1. Baseline CHA2DS2-VASc score and prognosis in octogenarians with non-ST segment elevation acute coronary syndrome

    International Journal of Clinical Practice, Vol. 75, Núm. 6

  2. COVID-19 and the impact of arterial hypertension—An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany)

    European Journal of Clinical Investigation, Vol. 51, Núm. 11

  3. COVID-19 anosmia and gustatory symptoms as a prognosis factor: a subanalysis of the HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

    Infection, Vol. 49, Núm. 4, pp. 677-684

  4. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19

    European Journal of Clinical Investigation, Vol. 51, Núm. 1

  5. Impact of frailty and atrial fibrillation in elderly patients with acute coronary syndromes

    European Journal of Clinical Investigation, Vol. 51, Núm. 5

  6. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry

    Internal and Emergency Medicine, Vol. 16, Núm. 4, pp. 957-966

  7. Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry

    American Heart Journal, Vol. 237, pp. 104-115

  8. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score

    Frontiers in Medicine, Vol. 8